Literature DB >> 8733107

An exercise on the feasibility of carrying out secondary economic analyses.

T Jefferson1, M Mugford, A Gray, V Demicheli.   

Abstract

Purchasers of health services need up to date information on cost-effectiveness of interventions to help in prioritising spending. But economists have not yet developed a formal methodology for reviewing and summing up evidence from individual economic evaluations which may have been conducted at different times and in different places, or indeed for assessing whether such systematic reviews are possible in this context. This paper discusses the problems of reviewing available economic information, using a body of literature on the economics of influenza vaccination to illustrate some relevant issues. First, the paper examines alternative methods for adjusting prices to take into account differences in currency and time periods: Retail Price Indices are compared with health specific inflation indices, and exchange rates are compared with Purchasing Power Parity (PPP) data. For the studies reviewed, the choice of conversion method made little practical difference. Secondly, the paper explores the possibility of summarising the results of a review in terms of quantities of resources used, rather than prices. This method is constrained by the available data, but could be more generally useful as it allows direct comparison of underlying technologies, and calculation of costs by attaching local unit costs to the resources associated with an intervention. These two exercises highlight many of the problems that arise in generalising from economic studies. Both methods need to be developed further if they are to be useful to decision makers.

Mesh:

Substances:

Year:  1996        PMID: 8733107     DOI: 10.1002/(SICI)1099-1050(199603)5:2<155::AID-HEC194>3.0.CO;2-O

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  7 in total

Review 1.  Willingness to pay and the valuation of programmes for the prevention and control of influenza.

Authors:  S Birch; A Gafni; B O'Brien
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

2.  Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective.

Authors:  S C Wood; V H Nguyen; C Schmidt
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

Review 3.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

Review 4.  Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Authors:  Maarten J Postma; Paul Jansema; Marianne L L van Genugten; Marie-Louise A Heijnen; Johannes C Jager; Lolkje T W de Jong-van den Berg
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Economics notes: Converting international cost effectiveness data to UK prices.

Authors:  Toby B Gosden; David J Torgerson
Journal:  BMJ       Date:  2002-08-03

Review 6.  Economic evaluations of varicella vaccination programmes: a review of the literature.

Authors:  Nancy Thiry; Philippe Beutels; Pierre Van Damme; Eddy Van Doorslaer
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

7.  Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria.

Authors:  J Lord; M J Thomason; P Littlejohns; R A Chalmers; M D Bain; G M Addison; A H Wilcox; C A Seymour
Journal:  J Epidemiol Community Health       Date:  1999-03       Impact factor: 3.710

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.